Biotech Voic­es: Coro­n­avirus will change biotech re­search with re­mote col­lab­o­ra­tions

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

When a field that de­pends on sci­en­tif­ic bench­work sud­den­ly moves on­line, what hap­pens to col­lab­o­ra­tions and the in­no­va­tion sup­ply chain? We are see­ing the an­swer to this ques­tion play out in re­al time dur­ing the Covid-19 cri­sis. Across the Unit­ed States and abroad, mea­sures to safe­guard against this se­ri­ous dis­ease have cre­at­ed an un­planned, mas­sive test for re­mote work in biotech­nol­o­gy.

Sci­en­tif­ic com­pa­nies face a unique chal­lenge dur­ing the shut­down: con­tin­u­ing their re­search. Lab-based work re­quires in-per­son, hu­man at­ten­tion, as many ex­per­i­ments are com­plex and re­quire spe­cial­ized ex­per­tise. These projects are of­ten achieved through re­search col­lab­o­ra­tions be­tween or­ga­ni­za­tions, re­quir­ing meet­ings to share da­ta, shared work en­vi­ron­ments, and deep dis­cus­sions. And their re­sults are price­less — these col­lab­o­ra­tions have the po­ten­tial to gen­er­ate ther­a­pies that save or im­prove mil­lions of lives in the fu­ture. This is why biotech­nol­o­gy com­pa­nies have been deemed an es­sen­tial in­dus­try and con­tin­ue to op­er­ate in some form dur­ing the shut­down.

Of course, the in­dus­try — like many oth­ers — has rapid­ly adapt­ed. With bans on trav­el and re­stric­tions on in-per­son work and meet­ings, many of the sci­en­tif­ic col­lab­o­ra­tions that gen­er­ate new ther­a­pies are now 100% vir­tu­al. This shift presents unique chal­lenges as well as op­por­tu­ni­ties.

It’s im­pos­si­ble to ful­ly re­place in-per­son work with Zoom video and con­fer­ence calls. Face-to-face com­mu­ni­ca­tion will con­tin­ue to be im­por­tant, even af­ter the acute coro­n­avirus pan­dem­ic eas­es and some sem­blance of nor­mal op­er­a­tions recom­mences. That said, it’s cru­cial that com­pa­nies con­tin­ue to pro­tect em­ploy­ees and pri­or­i­tize their com­fort and safe­ty. The need for safe, low-risk busi­ness en­vi­ron­ments will con­tin­ue to be nec­es­sary, and we will all need to ad­just and adapt to col­lab­o­ra­tions with less — and some­times no — in-per­son in­ter­ac­tions.

As the need for re­mote work con­tin­ues, it will dri­ve big changes in how biotech com­pa­nies ap­proach re­search col­lab­o­ra­tions and part­ner­ing ac­tiv­i­ty.

Sci­ence will be “de-den­si­fied”

Across in­dus­tries, busi­ness­es are look­ing for ways to “de-den­si­fy” work en­vi­ron­ments to pro­tect em­ploy­ees. Biotech is no dif­fer­ent. Un­til we have re­li­able and wide­ly-avail­able tests for Covid-19 — both an­ti­body tests and serol­o­gy tests — to sup­port safer work­spaces, labs will need to adapt. Al­ready, biotech com­pa­nies are cre­at­ing new work struc­tures to en­sure that em­ploy­ee health is pro­tect­ed and sci­en­tists spend the least amount of time to­geth­er in the lab.

New struc­tures with more re­mote work mean that sci­en­tif­ic teams will be­come greater ex­perts at plan­ning and com­mu­ni­ca­tion. At my com­pa­ny, for ex­am­ple, we have im­ple­ment­ed a shift-based ap­proach, send­ing teams in­to the lab for two-week sprints, fol­lowed by two weeks of re­mote of­fice work. With this sys­tem, we al­ways have a core team in the lab for es­tab­lished process­es such as tis­sue cul­ture, bio­chem­istry, in-vi­vo, phar­ma­col­o­gy, and more. These shifts are ac­com­pa­nied by tem­per­a­ture checks and oth­er mea­sures to en­sure our team feels and is safe, and that our labs are at low­est pos­si­ble risk for spread­ing Covid-19. Feed­back from our teams re­flects chal­lenges — we can­not work at the same den­si­ty or ef­fi­cien­cy as be­fore — but we al­so see that teams have learned to work more in­ti­mate­ly to com­pen­sate. Fur­ther­more, our most in­no­v­a­tive sci­en­tists are ac­cel­er­at­ing our ef­forts in bioin­for­mat­ics and the use of AI in bi­o­log­i­cal imag­ing and drug de­sign, all of which can be ac­com­plished re­mote­ly af­ter key da­ta have been gen­er­at­ed in the labs.

Re­search col­lab­o­ra­tions will be­come more glob­al

Biotech clus­ters like Boston, New York, and San Fran­cis­co have many ben­e­fits, one of which is den­si­ty of col­lab­o­ra­tors and part­ners, such as uni­ver­si­ties and Big Phar­ma play­ers. Big name com­pa­nies spend huge amounts of cap­i­tal on R&D col­lab­o­ra­tion, and many drugs are born from part­ner­ships based on phys­i­cal prox­im­i­ty.

Re­mote col­lab­o­ra­tion was al­ways tech­no­log­i­cal­ly pos­si­ble, and has been a key strat­e­gy for biotech for years. How­ev­er, hav­ing an in­no­va­tion chain dom­i­nat­ed by re­mote col­lab­o­ra­tion in the ear­ly dis­cov­ery space is an untest­ed con­cept. Now, we’re see­ing that glob­al col­lab­o­ra­tion is more vi­able than per­haps an­tic­i­pat­ed. With the right tools and process­es, sci­en­tif­ic teams can work well across bound­aries.

More glob­al col­lab­o­ra­tions au­to­mat­i­cal­ly lead to more di­ver­si­ty, which of­ten im­proves ideas and ap­proach­es. With dis­trib­uted col­lab­o­ra­tions, the qual­i­ty of re­search and find­ings will al­so grow. Bet­ter ther­a­peu­tics are a net pos­i­tive for the health­care in­dus­try and pa­tients.

Pri­or­i­ties will be­come more reg­i­ment­ed

Sci­ence is a cre­ative process, with room for wan­der­ing, imag­i­na­tive it­er­a­tion. Suc­cess­ful in­no­va­tion, how­ev­er, has al­ways re­quired dis­ci­plined con­cen­tra­tion. With re­duced lab ca­pac­i­ty due to de-den­si­fied work en­vi­ron­ments, com­pa­nies will now need to hone their fo­cus like nev­er be­fore.

For com­pa­nies with a sin­gle as­set, this will mean a laser-fo­cused ap­proach to re­search, with less room for tan­gen­tial work. For plat­form com­pa­nies — like my own — whose bi­o­log­i­cal in­sights al­low the tar­get­ing of mul­ti­ple dis­eases, teams will need to quick­ly de­cide which paths to pur­sue alone and which would fit bet­ter in col­lab­o­ra­tion. No mat­ter what, the “nice to dos” will fall away in fa­vor of the “need to dos.” Fast for­ward to the fu­ture, and this nec­es­sary triage may re­sult in a bumper crop of valu­able ther­a­peu­tics.

Best prac­tices for man­ag­ing a re­mote col­lab­o­ra­tion

Over my ca­reer, like many oth­ers, I’ve man­aged suc­cess­ful re­mote col­lab­o­ra­tions. In more than one case, a team has col­lab­o­rat­ed re­mote­ly for years with­out ever meet­ing in per­son. It is thrilling to watch work­ers who do meet in per­son un­der cir­cum­stances where, af­ter work­ing in­ti­mate­ly “alone, to­geth­er” over long dis­tances, it feels like a re­union of long-lost friends. But it is al­so note­wor­thy that these teams were very pro­duc­tive, even with­out ini­tial face-to-face col­lab­o­ra­tion.

For com­pa­nies fac­ing re­mote col­lab­o­ra­tions due to Covid-19, part­ners on both sides of the equa­tion will be fac­ing chal­lenges. The fol­low­ing best prac­tices ap­ply to all col­lab­o­ra­tions, but they’re more crit­i­cal than ever to­day:

  • Es­tab­lish clear vi­sion and goals: Whether in-per­son or re­mote, all re­search col­lab­o­ra­tions should have a shared vi­sion and mea­sur­able, clear goals. When teams are col­lab­o­rat­ing across re­mote lo­ca­tions with lit­tle to no in-per­son in­ter­ac­tion, this be­comes even more im­por­tant. Hav­ing a vi­sion is in­spir­ing, and it re­minds us what we’re work­ing to­ward. En­sure every­one is on the same page from day one, and build the vi­sion and goals in­to meet­ings and oth­er col­lab­o­ra­tive check­points.
  • Se­lect key col­lab­o­ra­tors thought­ful­ly: In any in­dus­try, good work re­lies on hav­ing the right team in place. Peo­ple who are in­cred­i­bly en­thu­si­as­tic and pas­sion­ate about their work can con­vey that ex­cite­ment even through a cam­era and over the phone. They should al­so be true ex­perts in com­mand of the da­ta, too — that goes for any col­lab­o­ra­tion, of course.
  • Choose the right tools — but don’t re­ly on them too much: Re­mote work is en­abled by ad­vanced tools like Slack and Zoom. But tools don’t com­mu­ni­cate — peo­ple com­mu­ni­cate. Col­lab­o­ra­tive teams need to agree on the tools sup­port­ing their work­flow, and they need to un­der­stand when, where, and what to com­mu­ni­cate. Se­lect tools that sup­port your goals, and en­sure every­one has been tech­ni­cal­ly trained and cul­tur­al­ly prepped on how to use them.
  • Prep thor­ough­ly: Tech­nol­o­gy can have short­com­ings, such as split-sec­ond lags for in­ter­na­tion­al calls, patchy au­dio, or lack of vi­su­al cues in body lan­guage. As a re­sult, or­ga­ni­za­tion and prepa­ra­tion are even more im­por­tant to cre­at­ing a good meet­ing cul­ture. Be­ing de­lib­er­ate, re­hears­ing for meet­ings, and us­ing time wise­ly will work won­ders in fa­cil­i­tat­ing smooth col­lab­o­ra­tion.
  • Be com­pas­sion­ate: Liv­ing through a cri­sis is fright­en­ing. To­day, many peo­ple are con­cerned for their health and for their loved ones. They are con­tend­ing with vast­ly shift­ed home en­vi­ron­ments, lack of child­care, and oth­er chal­lenges. Em­pa­thy is cru­cial. Build flex­i­bil­i­ty in­to col­lab­o­ra­tions to al­low sci­en­tists room to man­age dur­ing this un­prece­dent­ed time.

In­no­vat­ing for a new fu­ture in health

Biotech­nol­o­gy com­pa­nies have been de­clared es­sen­tial busi­ness­es for a rea­son — al­ready, mul­ti­ple com­pa­nies have mo­bi­lized to look for so­lu­tions to coro­n­avirus. From the im­me­di­ate cri­sis to dif­fi­cult dis­eases like Alzheimer’s and can­cer, our in­dus­try’s young com­pa­nies are the fu­ture of hu­man health. We are on track to find new ther­a­pies and cures for many dis­eases.

Col­lab­o­ra­tions are the lifeblood of our in­dus­try, and they will con­tin­ue. Our in­dus­try is in­ven­tive, and I am con­fi­dent that we will find new ways of work­ing that en­sure em­ploy­ee safe­ty and re­sult in more dis­trib­uted, more glob­al, and more fo­cused re­search. While these are un­cer­tain times, our in­dus­try-wide mis­sion to help pa­tients and save lives is as strong as ever. I en­cour­age com­pa­nies large and small to ap­proach re­mote col­lab­o­ra­tion not as an un­ten­able set­back, but rather as a new par­a­digm to con­tin­ue our cru­cial work in 2020 and be­yond.

Pearl Huang is the CEO of Cyg­nal Ther­a­peu­tics, an ear­ly-stage biotech­nol­o­gy com­pa­ny in Cam­bridge, MA.

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

2023 Spot­light on the Fu­ture of Drug De­vel­op­ment for Small and Mid-Sized Biotechs

In the context of today’s global economic environment, there is an increasing need to work smarter, faster and leaner across all facets of the life sciences industry.  This is particularly true for small and mid-sized biotech companies, many of which are facing declining valuations and competing for increasingly limited funding to propel their science forward.  It is important to recognize that within this framework, many of these smaller companies already find themselves resource-challenged to design and manage clinical studies themselves because they don’t have large teams or in-house experts in navigating the various aspects of the drug development journey. This can be particularly challenging for the most complex and difficult to treat diseases where no previous pathway exists and patients are urgently awaiting breakthroughs.

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product approved since last November, leaving many sponsors in limbo on what to expect.

That silence means that for more than 70 orphan-designated indications for more than 60 products, OOPD has issued no public determination on the seven-year orphan exclusivity in the Orange Book, and no new listings of orphan exclusivity appear in OOPD’s searchable database, as highlighted recently by George O’Brien, a partner in Mayer Brown’s Washington, DC office.

Albert Bourla, Pfizer CEO (Efren Landaos/Sipa USA/Sipa via AP Images)

Pfiz­er makes an­oth­er bil­lion-dol­lar in­vest­ment in Eu­rope and ex­pands again in Michi­gan

Pfizer is continuing its run of manufacturing site expansions with two new large investments in the US and Europe.

The New York-based pharma giant’s site in Kalamazoo, MI, has seen a lot of attention over the past year. As a major piece of the manufacturing network for Covid-19 vaccines and antivirals, Pfizer is gearing up to place more money into the site. Pfizer announced it will place $750 million into the facility, mainly to establish “modular aseptic processing” (MAP) production and create around 300 jobs at the site.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Vas Narasimhan, Novartis CEO (Thibault Camus/AP Images, Pool)

No­var­tis bol­sters Plu­vic­to's case in prostate can­cer with PhI­II re­sults

The prognosis is poor for metastatic castration-resistant prostate cancer (mCRPC) patients. Novartis wants to change that by making its recently approved Pluvicto available to patients earlier in their course of treatment.

The Swiss pharma giant unveiled Phase III results Monday suggesting that Pluvicto was able to halt disease progression in certain prostate cancer patients when administered after androgen-receptor pathway inhibitor (ARPI) therapy, but without prior taxane-based chemotherapy. The drug is currently approved for patients after they’ve received both ARPI and chemo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Rick Modi, Affinia Therapeutics CEO

Ver­tex-part­nered gene ther­a­py biotech Affinia scraps IPO plans

Affinia Therapeutics has ditched its plans to go public in a relatively closed-door market that has not favored Nasdaq debuts for the drug development industry most of this year. A pandemic surge in 2020 and 2021 opened the doors for many preclinical startups, which caught Affinia’s attention and gave the gene therapy biotech confidence in the beginning days of 2022 to send in its S-1.

But on Friday, Affinia threw in the S-1 towel and concluded now is not the time to step onto Wall Street. The biotech has put out few public announcements since the spring of this year. Endpoints News picked the startup as one of its 11 biotechs to watch last year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Af­ter M&A fell through, Ther­a­peu­tic­sMD sells hor­mone ther­a­py, con­tra­cep­tive ring for $140M cash plus roy­al­ties

TherapeuticsMD, a women’s health company whose one-time billion-dollar valuation seems a distant memory as its blockbuster aspirations petered out, is finally cashing out.

Australia’s Mayne Pharma is paying $140 million upfront to license essentially TherapeuticsMD’s whole portfolio, including two prescription drugs that treat conditions relating to menopause, a contraceptive vaginal ring as well as its prescription prenatal vitamin brands.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Big week for Alzheimer’s da­ta; As­traZeneca buys cell ther­a­py start­up; Dig­i­tal ther­a­peu­tics hits a pay­er wall; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

You may start to notice more stories exclusively available to Premium subscribers. This week alone, paid subscribers can read our in-depth reporting on Alzheimer’s data, digital therapeutics and Allogene’s cell therapy for solid tumors, as well as scoops on Twitter ads and Catalent. With your support, we can keep growing our team and spend more time on quality work. We have both individual and company plans available — check them out to unlock the full Endpoints experience.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Yuling Li, Innoforce CEO

In­no­force opens new man­u­fac­tur­ing site in Chi­na

Innoforce is off to the races at its new site in the city of Hangzhou, China.

The Chinese CDMO announced last week that it has started manufacturing at the new facility, which was built to offer process development and manufacturing operations for RNA, plasmid DNA, viral vectors and other cell therapeutics. It will also serve as Innoforce’s corporate HQ.

The company said it’s investing more than $200 million in the 550,000-square-foot manufacturing base for advanced therapies. The GMP manufacturing facility features space for producing plasmids with three 30-liter bioreactors. For viral vector manufacturing, Innoforce also has 200- and 500-liter bioreactors at its disposal, along with eight suites to make cell therapies. The site also includes several labs and warehouse spaces.

FDA grants or­phan drug des­ig­na­tion to Al­ger­non's ifen­prodil, while ex­clu­siv­i­ty re­mains un­clear

As the FDA remains silent on orphan drug exclusivity in the wake of a controversial court case, the agency continues to hand out new designations. The latest: Algernon Pharmaceuticals’ experimental lung disease drug ifenprodil.

The Vancouver-based company announced on Monday that ifenprodil received orphan designation in idiopathic pulmonary fibrosis (IPF), a chronic lung condition that results in scarring of the lungs.  Most IPF patients suffer with a dry cough, and breathing can become difficult.